literature

SARS_CoV_2 mutation literature information.

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.

PMID: 33903110 2021 Antimicrobial agents and chemotherapy

Result: The region coding for the spike protein accumulated a significant number of high-frequency (>90% of the viral population) changes, including a deletion leading to the removal of 9 amino acids in the N-terminal domain (from nt 21762 to nt 21788) and 3 nonsynonymous mutations: A23014C (E484D amino acid change according to S-protein-specific numbering), C23997G (P812R), and A24424C

Discussion: Noticeably, an in silico study of E484D predicted a higher ACE2 binding affinity that could render a more infectious SARS-CoV-2 variant, which is further supported by our ACE2-blocking experiments in which more ACE2 antibody is needed to decrease the infectivity of the adapted virus.

Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies.

PMID: 33880470 2021 bioRxiv

Abstract: We unveil, for the first time, that high-frequency mutations R346K/S, N439K, G446V, L455F, V483F/A, E484Q/V/A/G/D, F486L, F490L/V/S, Q493L, and S494P/L might compromise some of mAbs in clinical trials.

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.

PMID: 33758839 2021 bioRxiv

Introduction: The E484K mutation reduced serum neutralizing activity by ~5-fold and ~7-fold for RBD-NP and HexaPro (GMT 1x102) compared to wild-type (D614G) SARS-CoV-2 S, respectively, whereas the E484A and E484D mutations did not significantly affect the neutralizing activity induced by either immunogen.

Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.

PMID: 33758785 2021 Heliyon

Table: E484D

Browser Board

Co-occurred Entities

Filtrator